We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
Read MoreHide Full Article
AngioDynamics (ANGO - Free Report) recently announced the acquisition of BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC. Notably, the system will be integrated into the company’s core Oncology business. A 12-person commercial organization of Surgical Specialties will join AngioDynamics to expand the reach of its Oncology business.
Management expects the acquisition to be neutral to earnings in fiscal 2019.
Following the announcement, AngioDynamics’ share price inched up 0.3% to $21.53 at yesterday’s close. Meanwhile, shares of the company have rallied 26.3% against the industry’s decline of 5.8% in a year’s time.
The stock carries a Zacks Rank #4 (Sell).
Coming back to the news, BioSentry Tract Sealant System is the first of its kind and a major development in the prevention of lung biopsy-related pneumothorax (PTX). Notably, the system has received FDA clearance and also a CE Mark in Europe.
Going by a paper in the Journal of Thoracic Disease, a total of 234,030 estimated new lung and bronchus cancer cases are likely to be diagnosed in 2018.
Hence the buyout is likely to be a profitable one for AngioDynamics.
Market Prospects
A study by MarketsandMarkets shows that the global biopsy devices market is projected to reach $2.42 billion by 2022 from $1.74 billion in 2017, at a CAGR of 6.8%. The report further states that North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe.
We expect the trend to continue, given the rising prevalence of cancer and government initiatives to spread awareness about the disease.
Hence the latest move has been a well-timed one for AngioDynamics.
Oncology Unit at a Glance
AngioDynamics’ Oncology division includes highly coveted product lines like Microwave Ablation, Radiofrequency Ablation and NanoKnife.
In the recently reported fourth quarter of fiscal 2018, revenues at the segment grossed $12.1 million, up a significant 38% year over year. The upside can be attributed to strong growth seen by the Solero Microwave Ablation System.
Want More From the Industry?
A few better-ranked stocks from the Medical Instruments space are Intuitive Surgical (ISRG - Free Report) , Masimo Corporation (MASI - Free Report) and Inogen, Inc. (INGN - Free Report) .
Inogen’s long-term earnings growth rate is projected at 24.5%. The stock carries a Zacks Rank #2.
Masimo’s expected long-term earnings growth rate is 14.8%. The stock currently has a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
AngioDynamics' (ANGO) BioSentry Buyout to Boost Oncology
AngioDynamics (ANGO - Free Report) recently announced the acquisition of BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC. Notably, the system will be integrated into the company’s core Oncology business. A 12-person commercial organization of Surgical Specialties will join AngioDynamics to expand the reach of its Oncology business.
Management expects the acquisition to be neutral to earnings in fiscal 2019.
Following the announcement, AngioDynamics’ share price inched up 0.3% to $21.53 at yesterday’s close. Meanwhile, shares of the company have rallied 26.3% against the industry’s decline of 5.8% in a year’s time.
The stock carries a Zacks Rank #4 (Sell).
Coming back to the news, BioSentry Tract Sealant System is the first of its kind and a major development in the prevention of lung biopsy-related pneumothorax (PTX). Notably, the system has received FDA clearance and also a CE Mark in Europe.
Going by a paper in the Journal of Thoracic Disease, a total of 234,030 estimated new lung and bronchus cancer cases are likely to be diagnosed in 2018.
Hence the buyout is likely to be a profitable one for AngioDynamics.
Market Prospects
A study by MarketsandMarkets shows that the global biopsy devices market is projected to reach $2.42 billion by 2022 from $1.74 billion in 2017, at a CAGR of 6.8%. The report further states that North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe.
We expect the trend to continue, given the rising prevalence of cancer and government initiatives to spread awareness about the disease.
Hence the latest move has been a well-timed one for AngioDynamics.
Oncology Unit at a Glance
AngioDynamics’ Oncology division includes highly coveted product lines like Microwave Ablation, Radiofrequency Ablation and NanoKnife.
In the recently reported fourth quarter of fiscal 2018, revenues at the segment grossed $12.1 million, up a significant 38% year over year. The upside can be attributed to strong growth seen by the Solero Microwave Ablation System.
Want More From the Industry?
A few better-ranked stocks from the Medical Instruments space are Intuitive Surgical (ISRG - Free Report) , Masimo Corporation (MASI - Free Report) and Inogen, Inc. (INGN - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Inogen’s long-term earnings growth rate is projected at 24.5%. The stock carries a Zacks Rank #2.
Masimo’s expected long-term earnings growth rate is 14.8%. The stock currently has a Zacks Rank #2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>